Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2026)

Pacific Biosciences Of California has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $54000.0 in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 99.64% year-over-year to $54000.0 in Q1 2026; TTM through Jun 2026 was $54000.0, a 100.14% increase from a year earlier, with the FY2025 full-year figure at $15.0 million, down 62.5% from the prior year.
• Asset Writedowns and Impairment was $54000.0 for Q1 2026 at Pacific Biosciences Of California, down from $15.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $93.2 million in Q2 2024, with the low at -$53.2 million in Q4 2024.
• Average Asset Writedowns and Impairment over 5 years is $5.5 million, with a median of $878000.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment tumbled 1002.77% in 2024, then jumped 499900.0% in 2025.
• Over 5 years, Asset Writedowns and Impairment stood at $3.4 million in 2022, then surged by 75.39% to $5.9 million in 2023, then sank by 1002.77% to -$53.2 million in 2024, then soared by 128.2% to $15.0 million in 2025, then plunged by 99.64% to $54000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $54000.0 (Q1 2026), $15.0 million (Q1 2025), and -$53.2 million (Q4 2024), per Business Quant data.